A5052930169- Thyroid Cancer Diagnosis and Treatment
- Iron Metabolism and Disorders
- Thyroid Disorders and Treatments
- Gastric Cancer Management and Outcomes
- Pharmaceutical Practices and Patient Outcomes
- Medication Adherence and Compliance
- Diabetes Treatment and Management
- Health Systems, Economic Evaluations, Quality of Life
- Metabolism, Diabetes, and Cancer
Novo Nordisk (Switzerland)
2024
University Hospital of Bern
2015-2019
University of Bern
2018-2019
Real-world data provide insight into how medications perform in clinical practice. The PIONEER REAL Switzerland study aimed to understand outcomes with oral semaglutide adults type 2 diabetes (T2D). was a 34–44-week, multicentre, prospective, non-interventional, single-arm of T2D naïve injectable glucose-lowering medication who were initiated on routine primary endpoint change glycated haemoglobin (HbA1c) from baseline (BL) end (EOS); secondary endpoints included body weight (BW) BL EOS and...
Introduction Multimorbidity and polypharmacy are important risk factors for drug-related hospital admissions (DRAs). DRAs often linked to prescribing problems (overprescribing underprescribing), as well non-adherence with drug regimens different reasons. In this trial, we aim assess whether a structured medication review compared standard care can reduce in multimorbid older patients polypharmacy. Methods analysis OPtimising thERapy prevent Avoidable Multimorbid people is European...
Anaemia and thyroid dysfunction are common often co-occur. Current guidelines recommend the assessment of function in work-up anaemia, although evidence on this association is scarce.In 'European Prospective Investigation Cancer' (EPIC)-Norfolk population-based cohort, we aimed to examine prevalence type anaemia (defined as haemoglobin <13 g/dl for men <12 women) according different groups.The mean age 8791 participants was 59·4 (SD 9·1) years 55·2% were women. Thyroid present 437 (5·0%) 517...